Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.59 |
| ▸ | RAB9A | P51151 | 3/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.59 |
| ▸ | NPC1 | O15118 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | HPGD | P15428 | 2/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.59 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.59 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.59 |
| ▸ | RELA | Q04206 | 1/20 | 0.59 |
| ▸ | ATM | Q13315 | 1/20 | 0.59 |
| ▸ | APP | P05067 | 4/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 7/20 | 0.50 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.48 |
| ▸ | TTR | P02766 | 1/20 | 0.44 |
| ▸ | ALB | P02768 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | CNR1 | P21554 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19406064 | 0.81 | MAPT (0.62) | MAPTRAB9ASMN1; SMN2KDM4ENPC1 | |
| SCHEMBL144958 | 0.80 | MAPT (0.71) | MAPTRAB9ASMN1; SMN2KDM4ENPC1 | |
| SCHEMBL26293557 | 0.79 | MAPT (0.73) | MAPTRAB9ASMN1; SMN2KDM4ENPC1 | |
| SCHEMBL3200362 | 0.79 | APP (0.65) | RAB9ASMN1; SMN2NPC1APPTP53 | |
| SCHEMBL3193340 | 0.79 | APP (0.83) | RAB9ANPC1APP | |
| SCHEMBL20897609 | 0.78 | MAPT (0.71) | MAPTRAB9ASMN1; SMN2KDM4ENPC1 | |
| SCHEMBL20897629 | 0.78 | MAPT (0.71) | MAPTRAB9ASMN1; SMN2KDM4ENPC1 | |
| SCHEMBL16689757 | 0.78 | TTR (0.72) | MAPTRAB9ASMN1; SMN2KDM4ENPC1 | |
| SCHEMBL20898075 | 0.78 | MAPT (0.60) | MAPTRAB9ASMN1; SMN2KDM4ENPC1 | |
| SCHEMBL14740978 | 0.77 | MAPT (0.52) | MAPTRAB9ASMN1; SMN2KDM4ENPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101506201-A | Novel heteroaryl substituted benzoxazoles | ASTRAZENECA AB (SE) | 2009-08-12 | — | — | CN | claimed |
| EP-2035418-A1 | NOVEL HETEROARYL SUBSTITUTED BENZOXAZOLES | Astra Zeneca AB (SE) | 2009-03-18 | — | — | EP | claimed |
| US-20080027051-A1 | Novel Heteroaryl Substituted Benzoxazoles | ASTRAZENECA AB (SE) | 2008-01-31 | — | — | US | claimed |
| WO-2007149030-A1 | NOVEL HETEROARYL SUBSTITUTED BENZOXAZOLES | ASTRAZENECA AB (SE) | 2007-12-27 | — | — | WO | claimed |
| CN-101506201-B | Novel heteroaryl-substituted benzazoles derivatives | ASTRAZENECA AB | 2012-03-14 | — | — | CN | disclosed |
| US-7670591-B2 | Heteroaryl substituted benzoxazoles | ASTRAZENECA AB (SE) | 2010-03-02 | — | — | US | disclosed |
| US-7670591-B2 | Heteroaryl substituted benzoxazoles | ASTRAZENECA AB (SE) | 2010-03-02 | — | — | US | disclosed |
| US-7670591-B2 | Heteroaryl substituted benzoxazoles | ASTRAZENECA AB (SE) | 2010-03-02 | — | — | US | disclosed |
| CN-101506201-A | Novel heteroaryl substituted benzoxazoles | ASTRAZENECA AB (SE) | 2009-08-12 | — | — | CN | disclosed |
| US-20080027051-A1 | Novel Heteroaryl Substituted Benzoxazoles | ASTRAZENECA AB (SE) | 2008-01-31 | — | — | US | disclosed |
| US-20080027051-A1 | Novel Heteroaryl Substituted Benzoxazoles | ASTRAZENECA AB (SE) | 2008-01-31 | — | — | US | disclosed |
| US-20080027051-A1 | Novel Heteroaryl Substituted Benzoxazoles | ASTRAZENECA AB (SE) | 2008-01-31 | — | — | US | disclosed |
| WO-2007149030-A1 | NOVEL HETEROARYL SUBSTITUTED BENZOXAZOLES | ASTRAZENECA AB (SE) | 2007-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027051-A1 | Novel Heteroaryl Substituted Benzoxazoles | PSEN1, PSEN2, APP | MAPT 6/4885RAB9A 2657/4885SMN1; SMN2 1011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.